Skip to main navigation Skip to search Skip to main content

Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma

  • the ECHELON-1 Study Group
  • Mayo Clinic Rochester, MN
  • University of Manchester
  • Provincial Health Services Authority
  • Maria Sklodowska-Curie Institute of Oncology
  • Sungkyunkwan University
  • Centre Antoine Lacassagne
  • The University of Tennessee Graduate School of Medicine
  • University of Rochester
  • Stanford University
  • University of Copenhagen
  • Rutgers - The State University of New Jersey, New Brunswick
  • Medical University of Łódź
  • Washington University St. Louis
  • National Cancer Center Korea
  • Massachusetts General Hospital
  • Takeda Development Center Americas
  • Seagen Inc.
  • Memorial Sloan-Kettering Cancer Center

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry

Immunology and Microbiology